Ocuphire Pharma Results

DRSS Predicts Vision-Threatening Complications (PDR/DME) Percent of Eyes Progress to PDR at 1-Year, 3-Year, and 5-Year Visits by Baseline DR Severity Ocuphire PHARMA Percentage of Eyes that Worsen to PDR 100% 80% 60% 40% 20% 0% Early screening and treatment for DR can reduce vision loss by up to 94% 5% Mild NPDR (35) 14% 25% 12% 30% Moderate NPDR (43) 66% 71% +41 48% 52% 40% 26% 1. Early treatment diabetic retinopathy study research group. ophthalmology. 1991;98(5 suppl):823-33. 2. Diabetes control and complications trial research group. N Engl J Med. 1993;329(14):997-86. 3. Moderately Severe NPDR (47) Regardless of severity, all eyes worsen over time Severe NPDR (53) 80% 5 Year Follow-up 3 Year Follow-up 1 Year Follow-up Fathy C, Patel S, Sternberg P Jr, Kohanim S. Disparities in adherence to screening guidelines for diabetic retinopathy in the United States: a comprehensive review and guide for future directions. Semin Ophthalmol. 2016;31(4):364-377. doi: 10.3109/08820538.2016.1154170 15

View entire presentation